The Translational Kinase Tumor Inhibitor Discovery Consortium between Six Partners
On April 10, 2013, SARomics Biostructures, Prestwick Chemical and ProQinase together with the University of Turin, Italy, the Israel Structural Proteomics Center (ISPC) and the TechMedIll platform of the University of Strasbourg announced that they have created the Translational Kinase Tumor Inhibitor Discovery Consortium (TAKTIC). TAKTIC was funded with €1.1 million by the EU 7th Framework Program “Research for the Benefit of SMEs”.
A kinase is a type of enzymethat transfers phosphategroups fromhigh-energydonor moleculesto specific substrates. It is widely used in biology research. By targeting on specific kinases, certain therapeutic chances or effects could be gained. Thus this approach has become one of the most important therapeutic applications on clinical conditions, such as for treating cancer, diabetes and inflammatory diseases.
The TAKTIC Consortium combines each member’s technologies in the field of drug discovery, for example, the medicinal chemistry, kinase biochemistry and biology, high throughput platform for protein expression and crystallization. The merging of the highly complementary capabilities of the six partners within the TAKTIC Consortium enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases.